United Therapeutics is trading 4.6% up at $509.80 after executives scheduled a September 8, 2026 fireside chat at the Wells Fargo Healthcare Conference.
- The company recently received FDA acceptance for nebulized Tyvaso to treat idiopathic pulmonary fibrosis, potentially supporting investor interest.
- Neither announcement explicitly attributes the pre-market move, while broader markets are mixed-to-lower and do not clearly explain the gain.